OptoSeeker (追光生物) Raises ¥50M Seed Round Led by Shenzhen Capital Group

OptoSeeker (追光生物) Secures ¥50M Seed Financing

OptoSeeker (Optoseeker Biotechnology (Shenzhen) Co., Ltd.), a Shenzhen-based life-science instrument maker, has raised a Seed round of ¥50,000,000 CNY. The round was led by Shenzhen Capital Group and included participation from Lingyi Venture Capital (零以创投), Guangdong TCM Health Fund (广东中医药大健康基金), and 南山战新投 (Nanshan Strategic Emerging Industry Investment). The funding date is October 8, 2026.

What OptoSeeker Does

Founded in 2023, OptoSeeker is one of the few companies worldwide with proprietary optoelectronic tweezer (OET) core technology. The company develops life-science instruments that integrate OET with microfluidics, imaging, and software.

Its OptoBot product line is designed for high-throughput single-cell manipulation and functional screening. These capabilities support applications in antibody discovery, cell-line development, and cell and gene therapy. According to the company, products have been delivered to multiple customers.

In addition to its instrument business, OptoSeeker provides AI-oriented single-cell functional data services. The company has established strategic partnerships with MGI Tech and BioMap.

Funding Details

• Round type: Seed
• Amount: ¥50,000,000 CNY
• Date: October 8, 2026
• Lead investor: Shenzhen Capital Group
• Participating investors: Lingyi Venture Capital (零以创投), Guangdong TCM Health Fund (广东中医药大健康基金), 南山战新投 (Nanshan Strategic Emerging Industry Investment)

Why This Matters for the Life-Science Tools Market

The Seed round provides OptoSeeker with capital to advance its OET-based platform at a time when single-cell manipulation and functional screening are increasingly central to drug discovery and cell therapy development. The company's integrated approach—combining OET, microfluidics, imaging, and software—positions it in a specialized segment of the life-science instrument market.

OptoSeeker's strategic partnerships with MGI Tech and BioMap suggest a focus on combining hardware with data and AI capabilities. Its AI-oriented single-cell functional data services may complement its instrument offerings, creating a broader value proposition for customers in antibody discovery and cell-line development.

Acquisition Perspective

For acquirers in the life-science tools and diagnostics space, OptoSeeker represents an early-stage asset with proprietary core technology in optoelectronic tweezers. The company's ability to deliver products to multiple customers and its strategic partnerships may be attractive to larger instrument makers or life-science platforms seeking to add high-throughput single-cell manipulation capabilities.

The Seed round, led by Shenzhen Capital Group with participation from several regional and specialized funds, provides validation from investors with experience in deep tech and healthcare. As OptoSeeker scales its OptoBot product line and expands its data services, it could become a target for companies looking to integrate OET technology into broader workflows.

Outlook

With fresh capital, OptoSeeker is positioned to further develop its OET platform and expand commercial reach. The company's focus on antibody discovery, cell-line development, and cell and gene therapy aligns with growing demand for tools that enable precise single-cell analysis. Its existing partnerships and customer deliveries provide a foundation for growth, though competition in the life-science instrument market remains significant.

For now, the Seed round marks a key milestone for the Shenzhen-based company as it seeks to establish its proprietary OET technology as a standard in high-throughput single-cell functional screening.